- Exchange: Frankfurt
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Snapshot for Affymax Inc (A5Y)
| Open: | 1.103 | Day's Range: | 1.094 - 1.223 | Volume: | 42,602 |
|---|---|---|---|---|---|
| Previous Close: | 0.949 | 52wk Range: | 0.597 - 21.367 | 1-Yr Rtn: | -89.49% |
Key Statistics for A5Y
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. DAX | - |
| Earnings Per Share (USD) (ttm) | - |
| Est. EPS (USD) (12/2013) | -1.3460 |
| Est. PEG Ratio | - |
| Market Cap (M EUR) | 0.00 |
| Shares Outstanding (M) | 0.00 |
| 30 Day Average Volume | 8,068 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/08/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for A5Y
Company Profile & Key Executives for A5Y
Affymax Inc. is a clinical-stage biopharmaceutical company. The Company develops peptide-based drugs for the treatment of serious and life-threatening conditions such as kidney disease and cancer.
| Herbert C Cross "Herb"Chief Financial Officer | Anne-Marie DuliegeChief Medical Officer |
| Christine ConroySenior VP:Regulatory Affairs | Karin L WalkerVP:Finance/Chief Acctg Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
A5Y News
-
Industry News
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page